With the latest layoffs, Novartis expects to let go of around 800 employees by the end of 2028. More than half of the cuts ...

Many of the FDA’s decisions this quarter involve applications that have previously been delayed, declined or outright ...

The mid-stage disappointment in Alzheimer’s disease delivers another blow to Neuphoria Therapeutics, which in November last year was forced to launch a strategic business review after a Phase 3 trial ...

In AstraZeneca’s third trip to Asia this year, the pharma secured ex-China rights to a dual inhibitor of PDE3 and PDE4, which in a Phase 2b study significantly improved lung function and lowered ...

Bispecific antibodies represent a rapidly expanding class of biotherapeutics, presenting distinct innovation trends across ...

Vera Therapeutics’ atacicept, to be marketed as Trutakna, will go up against Novartis, Otsuka and possibly Vertex in the kidney disease primary IgA nephropathy after receiving an accelerated FDA ...

New data on Hengrui Pharma and Kailera Therapeutics’ investigational oral GLP-1 have validated the late-stage weight loss asset and paved the road for a regulatory submission in China, but analysts ...

Vertex Pharmaceuticals’ acquisition of Crinetics Pharmaceuticals is the largest pickup in the company’s history, according to analysts at BMO Capital Markets. Vertex Pharmaceuticals is absorbing ...

Patients treated with Bristol Myers Squibb’s Krazati in combination with cetuximab saw shorter median overall and progression-free survival than comparators on chemotherapy. Bristol Myers Squibb’s RAS ...

The centerpiece of the acquisition is Myricx Bio’s novel N-myristoyltransferase inhibitor payload platform, which could help Novartis develop antibody-drug conjugates that can overcome the limitations ...

After debuting on the public markets with $256.3 million and raking in an additional $472 million, Veradermics has emerged as one of biotech’s biggest post-IPO standouts. CEO Reid Waldman credits the ...